FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an ...

A once-a-day pill that could completely revolutionise the treatment of Alzheimer’s disease has reached a significant ...

Singapore-based biotech Hummingbird Bioscience has out-licensed its lead immunotherapy candidate, HMBD-002, to Australian ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Last week, it was announced that two new “breakthrough” treatments for Alzheimer’s had been turned down for NHS use. The tone ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

BigHat acquired, Frugi Biotechnology, a company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology, in 2022. They have five programs in internal pipeline and ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

A revolutionary new type of "Trojan horse" cancer therapy, now being deployed under the National Health Service in England, ...

Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell (SHA ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy  Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

A once-a-day pill called blarcamesine may slow memory loss and preserve independence—without the scary side effects or ...